ALE.F02

Phase 2Small molecule

ALE.F02 is one of 39 small molecule programs targeting Glomerulonephritis Rapidly Progressive. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Glomerulonephritis Rapidly ProgressiveRecruiting

CirrhosisActive, not recruiting

Glomerulonephritis Rapidly ProgressivePhase 2

Recruiting

CirrhosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

252 competitors in Cirrhosis

#DrugCompanyPhaseTrials

Proamatine

Takeda

Preclinical

9 2

Crestor

AstraZeneca

Preclinical

2 3

Thalomid

Bristol-Myers Squibb

Preclinical

1 4

Farxiga

AstraZeneca

Preclinical

1 5

Azulfidine

Pfizer

Preclinical

1 6

Dobutrex

Eli Lilly

Preclinical

1 7

HEPCLUDEX

Gilead

Preclinical

1 8

Cipro

Bayer

Preclinical

1 9

Coreg

Akero Therapeutics

Preclinical

6 10

Baraclude

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Glomerulonephritis Rapidly Progressive

NCT06047171

Clinical

Trials by Indication[1]

Cirrhosis1 trial

A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis

Completed·AAlentis Therapeutics AG·Phase 1·NCT05939947·41 enrolled

Glomerulonephritis Rapidly Progressive1 trial

A Randomized, Double-Blind, Placebo-Controlled Study of Intravenously Administered ALE.F02 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Renal Sparing in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Rapidly Progressive Glomerulonephritis

Recruiting·AAlentis Therapeutics AG·Phase 2·NCT06047171·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ALE.F02. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALE.F02 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALE.F02. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alentis Therapeutics AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAlentis Therapeutics AG

ALE.F02

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Cirrhosis1 trial

Glomerulonephritis Rapidly Progressive1 trial

References

Drug Info

Quick Facts

Related News